or
Bookmark and Share
Haemophilus adherence and penetration proteins
   
Document Number
US Patent 6245337
Issued Date
June 12, 2001
Link
Inventors
Map
Abstract
Haemophilus adhesion and penetration proteins, nucleic acids, vaccines and monoclonal antibodies are provided.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
5
Comments:
no comments yet
Published
June 12, 2001
Application Number
08/296,791
Filed
August 25, 1994
US Classification
424/256.1   424/190.1 435/69.1 435/69.3 530/350
Int'l Classification
C07K   14/285   (20060101)   C12N   9/52   (20060101)   C07K   14/195   (20060101)   C07K   16/12   (20060101)   A61K   38/00   (20060101)   A61K   39/00   (20060101)  
Examiner
USPTO Field of Search
424/190.1   424/256.1   530/350   435/69.1   435/69.3  
Related Patents
6815182 - Haemophilus adherence and penetration proteins - Owned by Washington, University (St. Louis, MO) The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)

Haemophilus adhesion and penetration proteins, nucleic acids, vaccines and monoclonal antibodies are provided.

7384640 - Mutant cholera holotoxin as an adjuvant - Owned by Wyeth Holdings Corporation (Madison, NJ) The United States of America as represented by the Uniformed Services University of the Health Sciences (Washington, DC) N/A

A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus or parasite. In a particular embodiment, the amino acid 29 is histidine. The mutant cholera holotoxin may contain at least one additional mutation in the A subunit at a position other than amino acid 29. The antigenic composition may include a second adjuvant in addition to the mutant cholera holotoxin.

7361355 - Mutant forms of cholera holotoxin as an adjuvant - Owned by Wyeth Holdings Corporation (Madison, NJ) The Regents of the University of Colorado, A Body Corporate (Aurora, CO)

Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

7285281 - Mutant forms of cholera holotoxin as an adjuvant - Owned by Wyeth Holdings Corporation (Madison, NJ) The Regents of the University of Colorado, A Body Corporate (Aurora, CO)

Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us